Treatment of diabetic hypertension

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 433-444

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Diabetic complications; Hypertension; Management

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METFORMIN; METOPROLOL; MINOXIDIL; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ADRENERGIC SYSTEM; ALBUMINURIA; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RESISTANCE; WEIGHT GAIN;

EID: 65449137918     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00983.x     Document Type: Review

References (74)

1. Bell DS. Hypertension in the person with diabetes. Am J Med Sci 1989; 297: 228-232.
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001; 37: 1053-1059.
3. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
5. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000; 321: 412-419.
6. American Diabetes Association. Position statement on treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201.
7. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
8. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 1-68.
9. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
10. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
11. Wright EM. Renal Na(+)-glucose cotransporters. Am J Renal Physiol 2001; 280: F10-F18.
12. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8: 19-28.
13. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
14. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
15. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
16. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/ or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004; 13: 319-324.
17. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
18. Malik RA, Williamson S, Abbott C et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
19. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
21. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
22. Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich) 2006; 8: 261-8.
23. Bybee KA, Das S, O'Keefe JH. The rationale and indications for angiotensin receptor blockers in heart failure. Heart Fail Clin 2006; 2: 81-88.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
25. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006; 48: 219-224.
26. Ridker PM, Danielson E, Rifai N, Glynn RJ,
27. Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 2006; 48: 73-79.
28. Petrie JR, Morris AD, Minamisawa K et al. Dietary sodium restriction impairs insulin sensitivity in non insulin-dependent diabetes mellitus. J Endocrinol Metab 1998; 83: 1552-1557.
29. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern Med 2004; 43: 9-17.
30. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404.
31. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
32. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
33. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43-50.
34. Jonas M, Reicher-Reiss H, Boyko V et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273-1277.
35. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
36. Movahed MR, Hashemzadeh M, Jamal M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels 2007; 22: 251-253.
37. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008; 101: 634-638.
38. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994; 11: 137-144.
39. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000; 95(Suppl. 1): I41-I45.
40. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: Data from the LIFE study. Lancet 2003; 362: 619-620.
41. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004; 364: 1684-1689.
42. Sipahi I, Tuzcu EM, Wolski KE et al. Beta-blockers and progression of coronary atherosclerosis: Pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 2007; 147: 10-18.
43. Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002; 112: 269-274.
44. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116: 460-465.
45. Connelly CM, McLaughlin RJ, Vogel WM, Apstein CS. Reversible and irreversible elongation of ischemic, infarcted, and healed myocardium in response to increases in preload and afterload. Circulation 1991; 84: 387-399.
46. Coghlan HC, Coghlan L. Cardiac architecture: Gothic versus Romanesque. A cardiologist's view. Semin Thorac Cardiovasc Surg 2001; 13: 417-430.
47. Bell DSH. Use of beta blockers in the patient with diabetes. Endocrinologist 2003; 13: 116-123.
48. Weber K, Bohmeke T, van der Does R, Taylor SH. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996; 10: 113-117.
49. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987; 2: 650-653.
50. Bell DS. Lower limb problems in diabetic patients. What are the causes? What are the remedies? Postgrad Med 1991; 89: 237-243.
51. Bell DS, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract 1997; 3: 281-283.
52. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40-43.
53. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
54. Hoffman RP, Sinkey CA, Kienzle MG, Anderson EA. Muscle sympathetic nerve activity is reduced in IDDM before overt autonomic neuropathy. Diabetes 1993; 42: 375-380.
55. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
56. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
57. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065-1070.
58. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003; 16(Pt 1): 381-386.
59. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.
60. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-959.
61. Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on preexisting and new on-set diabetes in patients with chronic heart failure iv- data from the Carvedilol or Metoprolol. European Trial (COMET). Heart 2007; 93: 968-973.
62. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.
63. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-2236.
64. Fonseca V, Bakris GL, Bell DS et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 2007; 24: 759-763.
65. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentrations in diabetic hypertensive patients. Diabetes Obes Metab 2008. PMID 18564334. (Epub ahead of print).
66. McGill JB, Bakris GL, Fonseca V et al. Beta-blocker use and diabetes symptom score: Results from the GEMINI study. Diabetes Obes Metab 2007; 9: 408-417.
67. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
68. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
69. Byington RP, Furberg CD, Craven TE, Pahor M, Sowers JR. Isradipine in prediabetic hypertensive subjects. Diabetes Care 1998; 21: 2103-2110.
70. Jamerson KA, for the ACCOMPLISH Investigators. Avoiding cardiovascular events with combination therapy in patients living with systolic hypertension. Chicago: American College of Cardiology Scientific Sessions, 2008.
71. Wassertheil-Smoller S, Psaty B, Greenland P et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004; 292: 2849-2859.
72. Purewal TS, Watkins PJ. Postural hypotension in diabetic autonomic neuropathy: A review. Diabet Med 1995; 12: 192-200.
73. Clements RS Jr, Bell DSH. Diagnostic pathogenetic and therapeutic aspects of diabetic neuropathy. In: Cohen MP, Foa PP eds. Special Topics in Endocrinology and Metabolism. New York: A.R. Liss, Inc., 1981; 1-143.
74. Bell DSH, O'Keefe JH, Bakris GL. Handbook of Diabetic Hypertension. Royal Oaks: Physicians Press, 2006.